Real World Patient Journey and Healthcare Resource Utilization of HR+/HER2- Breast Cancer Patients in the Brazilian Private Healthcare System

Author(s)

Bigoni A1, Kim H2, da Silva AL2, Bueno C2, Leonel L3, Santos A3, Goularte V3
1Novartis, Sao Paulo, SP, Brazil, 2Novartis, São Paulo, SP, Brazil, 3IQVIA, São Paulo, SP, Brazil

OBJECTIVES: Breast cancer (BC) represents the most prevalent cancer among Brazilian women, with notable mortality rates and economic impacts. The most common subtype in Brazil is hormone receptor (HR)-positive and human epidermal growth factor receptor-2 (HER2)-negative. This study focuses on understanding the, patient journey, and treatment patterns of this subtype in the Brazilian private healthcare system.

METHODS: This observational, retrospective database study analyzes HR+/HER2- breast cancer patient management within the Brazilian private healthcare system. In the study we included patients that had a medical record of breast cancer (ICD-10 code C50) from January 2017 to April 2023, diagnosed as HR-positive, HER2-negative, and treated within the private healthcare system. Data is derived from the iHealth Group, which extracted using a NLP model and applied to various providers and institutions. Descriptive statistics were applied for continuous and categorical variables.

RESULTS: The study included 5,330 patients, with a mean age of 57.66 years. Most patients were treated in the Southeast region of Brazil(66.65%), reflecting the distribution of private healthcare facilities. Patients had on average, 30.36 (SD 20.07) visits to health facilities during treatment. A total of 4,130 (77.49%) of patients underwent surgery, with 70.0% receiving chemotherapy and 88.2% undergoing radiation therapy. Hormonal therapy was administered to 91.8% of patients. Notably, 1519 (81.48%) patients that started the treatment at early stages (I and II) had surgery, while only 972(75.27%) of later stage patients(III and IV), underwent surgery. However, early stages patients had less mastectomy when compared to later stages (26% vs. 36%).

CONCLUSIONS: This study has successfully provided a detailed overview of the journey and health burden impact of HR+/HER2- breast cancer patients within Brazil's private healthcare system. Our findings offer insights into the treatment patterns, and associated burden of managing HR+/HER2- breast cancer in a private healthcare context. More details are available on the poster.

Conference/Value in Health Info

2024-11, ISPOR Europe 2024, Barcelona, Spain

Value in Health, Volume 27, Issue 12, S2 (December 2024)

Code

HSD82

Topic

Study Approaches

Disease

No Additional Disease & Conditions/Specialized Treatment Areas, Oncology

Your browser is out-of-date

ISPOR recommends that you update your browser for more security, speed and the best experience on ispor.org. Update my browser now

×